[
  {
    "ts": null,
    "headline": "Jim Cramer On AbbVie: Makes “Sense To Start a Position in the Stock”",
    "summary": "Calling AbbVie Inc. (NYSE:ABBV) one of his “absolute favorites” during the recent episode of Mad Money, Cramer said: “Or how about one of my absolute favorites right here too, AbbVie. Now here’s a drug company with no patent cliff in sight whatsoever. Got tremendous franchises in neurology, oncology, immunology, and medical aesthetics, among others. Because […]",
    "url": "https://finnhub.io/api/news?id=59d3265d0a33b91103e69fb2d841ea54cbdde26db1634b5eef35481e3b475b74",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747422541,
      "headline": "Jim Cramer On AbbVie: Makes “Sense To Start a Position in the Stock”",
      "id": 134567800,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Calling AbbVie Inc. (NYSE:ABBV) one of his “absolute favorites” during the recent episode of Mad Money, Cramer said: “Or how about one of my absolute favorites right here too, AbbVie. Now here’s a drug company with no patent cliff in sight whatsoever. Got tremendous franchises in neurology, oncology, immunology, and medical aesthetics, among others. Because […]",
      "url": "https://finnhub.io/api/news?id=59d3265d0a33b91103e69fb2d841ea54cbdde26db1634b5eef35481e3b475b74"
    }
  },
  {
    "ts": null,
    "headline": "Some May Be Optimistic About AbbVie's (NYSE:ABBV) Earnings",
    "summary": "AbbVie Inc.'s ( NYSE:ABBV ) stock was strong despite it releasing a soft earnings report last week. We think that...",
    "url": "https://finnhub.io/api/news?id=a199fcabfb5a7eac13bca8eced34c32599f74e30ea028a4d8a56b97bcded4213",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747419313,
      "headline": "Some May Be Optimistic About AbbVie's (NYSE:ABBV) Earnings",
      "id": 134567801,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc.'s ( NYSE:ABBV ) stock was strong despite it releasing a soft earnings report last week. We think that...",
      "url": "https://finnhub.io/api/news?id=a199fcabfb5a7eac13bca8eced34c32599f74e30ea028a4d8a56b97bcded4213"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=1f092153dc1a0686bf22cb0f053c48ec6d8e734d83876aca909b54e6e0c58df6",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747413060,
      "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "id": 134532743,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=1f092153dc1a0686bf22cb0f053c48ec6d8e734d83876aca909b54e6e0c58df6"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer's Turnaround Story Is Stronger Than You Think",
    "summary": "Pfizer's Turnaround Story Is Stronger Than You Think",
    "url": "https://finnhub.io/api/news?id=f1aa39358b70fbcabefaa095b1113b67f395143069dd178c847bce24ceee8311",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747405928,
      "headline": "Pfizer's Turnaround Story Is Stronger Than You Think",
      "id": 134500844,
      "image": "",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=f1aa39358b70fbcabefaa095b1113b67f395143069dd178c847bce24ceee8311"
    }
  },
  {
    "ts": null,
    "headline": "Pharma Stock Roundup: BAYRY Q1 Earnings, NVO & GSK's New Deals",
    "summary": "Bayer reports first-quarter results. NVO and GSK announce licensing deals with smaller biotechs.",
    "url": "https://finnhub.io/api/news?id=954b83d444900fa2f4c249293cca25d712dd80f690d9eea6fc1cd6a04da727b3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747397160,
      "headline": "Pharma Stock Roundup: BAYRY Q1 Earnings, NVO & GSK's New Deals",
      "id": 134498597,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Bayer reports first-quarter results. NVO and GSK announce licensing deals with smaller biotechs.",
      "url": "https://finnhub.io/api/news?id=954b83d444900fa2f4c249293cca25d712dd80f690d9eea6fc1cd6a04da727b3"
    }
  },
  {
    "ts": null,
    "headline": "June 3, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ABBV",
    "summary": "NEW YORK, May 16, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. of a class action securities lawsuit. ...",
    "url": "https://finnhub.io/api/news?id=8c928e51926709f010a6df2fd3a716691d2967d903792f9f68c2f68f3cd566ac",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747374376,
      "headline": "June 3, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ABBV",
      "id": 134495506,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "NEW YORK, May 16, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. of a class action securities lawsuit. ...",
      "url": "https://finnhub.io/api/news?id=8c928e51926709f010a6df2fd3a716691d2967d903792f9f68c2f68f3cd566ac"
    }
  },
  {
    "ts": null,
    "headline": "1 Healthcare Stock to Keep an Eye On and 2 to Ignore",
    "summary": "Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 6.7%. This performance was disappointing since the S&P 500 held its ground.",
    "url": "https://finnhub.io/api/news?id=31aa03aefa2686f28ec6d47c2721beeb5862d9e2b86080b6650f4c85c543ee86",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747369991,
      "headline": "1 Healthcare Stock to Keep an Eye On and 2 to Ignore",
      "id": 134498598,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 6.7%. This performance was disappointing since the S&P 500 held its ground.",
      "url": "https://finnhub.io/api/news?id=31aa03aefa2686f28ec6d47c2721beeb5862d9e2b86080b6650f4c85c543ee86"
    }
  }
]